Make Me Wet® Estrogen (5 mg estradiol) Vaginal dissolving troche (24 doses)
Topically inserted estrogen is the most successful vaginal rejuvenator for all women. This re-establishes youthful thickness, elasticity, and lubrication to the walls and the supporting structures of the vagina. Nearly every reconstructive surgeon prescribes this for the patients to create the healthiest tissues.
- makes vagina wet, responsive, and rough
- use for a super juicy special encounter
- estrogen decreases in all women after age 33
- only safe way is vaginal insert – where needed most
- Vie’s formulation provides an estrogen + progesterone suppository. The estrogen is in the lowest safe dose (no increase medical risk for long-term use). Progesterone is essential for hormone balance
- usage protocols are sent on receipt of order
We Also Recommend for You
Methyl B-12 (5000 mcg Capsules), Oral$60.00 Add to cart
Armour Thyroid T3/T4 (60 mg)$180.00 Add to cart
Sildenafil + The Love Hormone® Oxytocin and Sexy Gum®, Oral$60.00 Select options
Tadalafil + The Love Hormone® Oxytocin, Oral$60.00 Select options
More Please® Multiorgasm Pill Cabergoline, Oral$96.00 Select options
The Pleasure Pill® Apomorphine (15 Troches), Oral$60.00 Add to cart
Herpes Blocker® Valcyclovir (500 mg tablets), Oral$30.00 Add to cart
Screem Creem® (30 grams = 30 cc)$50.00 Select options
PT-141 (10,000 mcg/ml), Injectable$240.00 Add to cart
Progesterone, Oral$124.00 – $200.00 Select options
Period Blocker®, Oral$90.00 Select options
The Love Hormone® – Oxytocin intranasal (5 ml = 50 sprays)$75.00 Add to cart
notes: Make Me Wet® suppository. This Vie product is designed to provide women with the ability to increase wetness of the vagina for sex. This can make special encounters even more special. It is also to be used in patients with age related vaginal thinning and loss of roughness.
As a reconstructive plastic surgeon, we regularly prescribed vaginal estrogen to rebuild and strengthen the vaginal tissues prior to working on them.
The very low-dose of estrogen in this suppository has been shown to be safe in numerous women studies. The estrogen is applied, absorbed, and used right where it is needed. Any systemic pour- over is low and short lived. The estrogen is balanced with progesterone to keep the vagina hormone balance proper.
Because of the scare of estrogen related cancer, any women with history of breast, cervical, or uterine cancer should have detailed face to face discussions with their PCP/GYN for low dose vaginal suppositories or any other estrogen treatment.
To determine the association between use of vaginal estrogen and risk of a global index event (GIE), defined as time to first occurrence of coronary heart disease (CHD), invasive breast cancer, stroke, pulmonary embolism, hip fracture, colorectal cancer, endometrial cancer, or death from any cause.
For this prospective observational cohort study, we used data from participants of the Women’s Health Initiative Observational Study, who were recruited at 40 US clinical centers, aged 50 to 79 years at baseline and did not use systemic estrogen therapy during follow-up (n = 45,663, median follow-up 7.2 years). We collected data regarding incident CHD, invasive breast cancer, stroke, pulmonary embolism, hip fracture, colorectal cancer, endometrial cancer, death, and self-reported use of vaginal estrogen (cream, tablet). We used Cox proportional-hazards regression models to adjust for covariates.
Among women with an intact uterus, the risks of stroke, invasive breast cancer, colorectal cancer, endometrial cancer, and pulmonary embolism/deep vein thrombosis were not significantly different between vaginal estrogen users and nonusers, whereas the risks of CHD, fracture, all-cause mortality, and GIE were lower in users than in nonusers (GIE adjusted hazard ratio 0.68, 95% confidence interval 0.55-0.86). Among hysterectomized women, the risks of each of the individual GIE components and of the overall GIE were not significantly different in users versus nonusers of vaginal estrogen (GIE adjusted hazard ratio 0.94, 95% confidence interval 0.70-1.26).
The risks of cardiovascular disease and cancer were not elevated among postmenopausal women using vaginal estrogens, providing reassurance about the safety of treatment.